Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial.

OBJECTIVE Binge eating disorder is associated with obesity. Topiramate is an antiepileptic agent associated with weight loss. The objective of this study was to evaluate topiramate in the treatment of binge eating disorder associated with obesity. METHOD For this 14-week, double-blind, flexible-dose (25-600 mg/day) topiramate trial, 61 outpatients (53 women, eight men) with binge eating disorder who were obese (body mass index >/=30 kg/m(2)) were randomly assigned to receive topiramate (N=30) or placebo (N=31). The primary efficacy measure was binge frequency. The primary analysis of efficacy was a repeated-measures random regression with treatment-by-time as the effect measure. RESULTS Compared with placebo, topiramate was associated with a significantly greater rate of reduction in binge frequency, binge day frequency, body mass index, weight, and scores on the Clinical Global Impression severity scale and the Yale-Brown Obsessive Compulsive Scale (modified for binge eating). Topiramate was also associated with significantly greater reductions in binge frequency (topiramate: 94%, placebo: 46%) and binge day frequency (topiramate: 93%, placebo: 46%) and with a significantly higher level of response than placebo. The mean weight loss for topiramate-treated subjects who completed the study was 5.9 kg. Median topiramate dose was 212 mg/day (range=50-600). Nine patients (three receiving placebo, six given topiramate) discontinued because of adverse events. The most common reasons for discontinuing topiramate were headache (N=3) and paresthesias (N=2). CONCLUSIONS Topiramate was efficacious and relatively well tolerated in the short-term treatment of binge eating disorder associated with obesity.

[1]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[2]  W. Goodman,et al.  The Yale-Brown Obsessive Compulsive Scale. II. Validity. , 1989, Archives of general psychiatry.

[3]  W. Agras,et al.  Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. , 1990, The American journal of psychiatry.

[4]  S D Imber,et al.  Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. , 1993, Archives of general psychiatry.

[5]  B. Stanley,et al.  Lateral hypothalamic injections of glutamate, kainic acid,d,l-α-amino-3-hydroxy-5-methyl-isoxazole propionic acid or N-methyl-d-aspartic acid rapidly elicit intense transient eating in rats , 1993, Brain Research.

[6]  A. Stunkard,et al.  d-fenfluramine treatment of binge eating disorder. , 1996, The American journal of psychiatry.

[7]  R. Davis,et al.  Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. , 1997, Drugs.

[8]  P. Diggle,et al.  Analysis of Longitudinal Data. , 1997 .

[9]  C. Lewis,et al.  Prevalence of binge eating disorder, obesity, and depression in a biracial cohort of young adults , 1998, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[10]  H G Pope,et al.  Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. , 1998, The American journal of psychiatry.

[11]  D. Williamson,et al.  Binge eating disorder: A review of the literature after publication of DSM-IV , 1999, Eating and weight disorders : EWD.

[12]  F. Horber,et al.  Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. , 1999, The International journal of eating disorders.

[13]  Y. Deshaies,et al.  Influence of topiramate in the regulation of energy balance. , 2000, Nutrition.

[14]  S. McElroy,et al.  Treatment of binge-eating disorder with topiramate: a clinical case series. , 2000, The Journal of clinical psychiatry.

[15]  P. Keck,et al.  Placebo-controlled trial of sertraline in the treatment of binge eating disorder. , 2000, The American journal of psychiatry.

[16]  S. Yanovski,et al.  Obesity: what mental health professionals need to know. , 2000, The American journal of psychiatry.

[17]  D. Alexoff,et al.  Topiramate selectively attenuates nicotine‐induced increases in monoamine release , 2001, Synapse.

[18]  T. Wadden,et al.  Psychosocial aspects of obesity and obesity surgery. , 2001, The Surgical clinics of North America.

[19]  B. Saelens,et al.  A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with binge-eating disorder. , 2002, Archives of general psychiatry.

[20]  H. Berthoud,et al.  Behavioral analysis of anorexia produced by hindbrain injections of AMPA receptor antagonist NBQX in rats. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[21]  P. Keck,et al.  A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. , 2002, The Journal of clinical psychiatry.

[22]  D. V. van Kammen,et al.  Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. , 2002, The Journal of clinical psychiatry.